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The developmental role of the T-box transcription factor Tbx1 is exquisitely dosage-sensitive. In this study,
we performed a microarray-based transcriptome analysis of E9.5 embryo tissues across a previously gener-
ated Tbx1 mouse allelic series. This analysis identiﬁed several genes whose expression was affected by Tbx1
dosage. Interestingly, we found that the expression of the gene encoding the cardiogenic transcription factor
Mef2c was negatively correlated to Tbx1 dosage. In vivo data revealed Mef2c up-regulation in the second
heart ﬁeld (SHF) of Tbx1 null mutant embryos compared with wild-type littermates at E9.5. Conversely,
Mef2c expression was decreased in the SHF and in somites of Tbx1 gain-of-function mutants. These results
are consistent with the described role of Tbx1 in suppressing cardiac progenitor cell differentiation and in-
dicate also a negative effect of Tbx1 on Mef2c during skeletal muscle differentiation. We show that Tbx1 oc-
cupies conserved regulatory regions of the Mef2c locus, suggesting a direct effect on Mef2c transcription.
However, we also show that Tbx1 interferes with the Gata4  Mef2c regulatory pathway. Overall, our study
uncovered a target of Tbx1 with critical developmental roles, so highlighting the power of the dosage gradi-
ent approach that we used.
INTRODUCTION
The T-box transcription factor TBX1 is encoded by the main
gene haploinsufﬁcient in DiGeorge syndrome, which is char-
acterized by congenital heart defects, hypo/aplasia of the para-
thyroid and thymus glands, craniofacial dysmorphism as well
as learning and behavioral abnormalities (1–5). Mutation of
murine Tbx1 can model the DiGeorge syndrome phenotype
(6–8). A progressive dosage reduction in Tbx1 mRNA is asso-
ciated with the non-linear increase in phenotypic severity (9)
while over-expression of Tbx1 results in structural heart and
thymic defects (10), conﬁrming that Tbx1 function, during
embryonic development, is exquisitely dosage-sensitive.
Uncovering the genetic and phenotypic changes resulting
from Tbx1 haploinsufﬁciency might help dissection of
molecular mechanisms underlying the DiGeorge syndrome
etiology.
Loss of Tbx1 is associated with reduced proliferation and
premature differentiation in the second heart ﬁeld (SHF)
(11–14). Accordingly, Fgf8 and Fgf10 were down-regulated
in Tbx1
2/2 mutants (13,15,16) while genes required for myo-
cardial differentiation (like Raldh2, Gata4 and Tbx5) were
ectopically expressed (13).
The mechanisms by which Tbx1 regulates its targets are not
all clear; there are now examples of transcription-dependent
and transcription-independent actions. For example, in vitro
and in vivo evidences show that Tbx1 positively regulates
expression of the Vegfr3 gene through interaction with a
T-box-binding element (TBE) (17), as expected for T-box
transcription factors.
On the other hand, it is also clear that Tbx1 can function in a
transcription-independent manner. Indeed, Tbx1 is able to
negatively regulate the bone morphogenic protein–Smad1
pathway by binding Smad1 and thus preventing the Smad1–
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Furthermore, Tbx1 can interact with the serum response
factor (Srf) and promote its proteasome-mediated degradation
(17), which, in turn, results in cardiac actin and a-smooth
muscle actin protein down-regulation (17,20,21). This non-
transcriptional interaction, although not yet completely clari-
ﬁed, probably contributes to the inhibition of cardiomyocyte
differentiation observed in vivo (13,14).
In this study, starting from microarray-based gene expres-
sion data, collected across an allelic series of Tbx1 embryo
mutants, we found that Tbx1 negatively modulates Mef2c
through several mechanisms.
Mef2c belongs to the MEF2 (myocyte-speciﬁc enhancer-
binding factor 2) subfamily of MADS [MCM1 (Minichromo-
some Maintenance 1 Protein), AG (Agamous), DEFA (Deﬁ-
ciens) and SRF (Serum Response Factor)] transcription
factors (22). Mef2 genes are expressed in cardiac, smooth
and skeletal muscle cells, endothelial cells as well as in a
restricted set of other tissues (23–25). Targeted inactivation
of the Mef2c gene in the mouse resulted in cardiac and vascu-
lar defects and embryonic lethality at E9.5 (26–28). In par-
ticular, in Mef2c
2/2 mice, the heart tube does not undergo
looping morphogenesis, the future right ventricle does not
form and several cardiac muscle genes are down-regulated.
These data indicate a key role of Mef2c in the transcriptional
pathways controlling myocyte differentiation.
We provide in vivo and in vitro data, indicating that Tbx1
plays an inhibitory role onto the Gata4 Mef2c regulatory
pathway, and we propose that this is a mechanism by which
Tbx1 affects muscle cell differentiation.
Our data also highlight the power of multiallelic gene ex-
pression analysis as a tool to identify developmentally critical
genes that correlate genotype-dependent phenotypic changes
to genome-wide transcriptional features.
RESULTS
Identiﬁcation of Tbx1 dosage-sensitive transcripts
We have previously generated a series of genotypes associated
with a nearly continuous variation of Tbx1 mRNA dosage
between 0 and 100% of the wild-type (wt) level by combining
two different hypomorphic alleles, Tbx1
Neo2 and Tbx1
Neo, and
a null allele, Tbx1
2 (9). To identify Tbx1 dosage-dependent
genes in vivo, we performed a microarray-based transcriptome
analysis across the allelic series; RNA isolated from whole
E9.5 embryos with nine different genotypes (9) was hybri-
dized to Affymetrix GeneChip Mouse Genome 430 2.0
arrays. For each genotype, we used two embryos, each hybri-
dized to one array; thus, we analyzed a total of 18 arrays (the
whole set of results has been deposited in NCBI’s Gene Ex-
pression Omnibus and is accessible through GEO Series ac-
cession number GSE33064; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=rxiphqgaeyioipy&acc=GSE33064).
We developed a data analysis strategy to identify genes that
respond signiﬁcantly to dosage variation of Tbx1 mRNA (see
Materials and Methods) and we found 2230 transcripts with
signiﬁcant differential expression (Supplementary Material,
Table S1). At a second ﬁltering step (see Materials and
Methods), we narrowed down the list to 497 transcripts (in
addition to Tbx1) differentially expressed across the allelic
series (Supplementary Material, Table S2). Among these
genes, we found very limited overlaps with previously
reported gene lists derived from Tbx1 mutants (13,29); these
genes are highlighted in green color in Supplementary Mater-
ial, Table S2. However, those studies were carried out using
different developmental stages and different experimental
approaches that did not use allelic series.
We applied a Gene Ontology (GO) search to the more strin-
gent data set using DAVID (30,31) and found 14 GO categor-
ies that are signiﬁcantly enriched (Supplementary Material,
Table S3).
We also carried out a cluster analysis that returned four
main clusters (Fig. 1). Cluster 2 includes Tbx1 and transcripts
that have an expression trend similar to Tbx1 across geno-
types. Cluster 3 behaves in an opposite way as transcripts in
this group tend to be more expressed as Tbx1 expression
goes down. Clusters 1 and 4, which are also the richest in tran-
scripts (see Supplementary Material, Table S4, for transcript
content of clusters), are very different and have somewhat
complementary patterns. In these two clusters, there appears
to be a threshold-like effect at dosages between experimental
points 4 and 5, corresponding to genotypes Tbx1
+/2 and
Tbx1
Neo2/Neo2, which are associated with a small overall differ-
ence in Tbx1 RNA dosage (10–15%) (9), but genetically, they
have an important difference, i.e. the former has an intact wt
allele and the latter has none. How this genetic difference
can translate into the expression patterns represented in Clus-
ters 1 and 4 remains to be investigated.
Tbx1 negatively regulates Mef2c expression
Among the 497 differentially expressed genes, we noted that
Mef2c expression increased as Tbx1 dosage decreased (simi-
larly to Cluster 3 of Fig. 1; Supplementary Material,
Table S2). Mef2c is important for heart development and car-
diomyocyte differentiation. The heart of Mef2c homozygous
mutant mice does not undergo looping and has gross abnor-
malities in the outﬂow tract, while the right ventricle fails to
form (28), suggesting a key role for Mef2c in SHF develop-
ment. In particular, it regulates transcriptional pathways con-
trolling differentiation. So, the negative modulation of Mef2c
expression by Tbx1 could contribute to explain the role of
Tbx1 in suppressing cell differentiation (14).
We conﬁrmed Mef2c up-regulation in Tbx1
2/2 embryos by
quantitative real-time reverse transcriptase–polymerase chain
reaction (qRT–PCR) of mRNA from E9.5 whole embryos
(Fig. 2A). In addition, in situ hybridization (ISH) on embryo
cryosections at E9.5 revealed up-regulation and ectopic
expression of Mef2c in the SHF of Tbx1
2/2 mutants
(Fig. 2F–I) compared with wt littermates (Fig. 2B–E). If
Mef2c expression is Tbx1 dosage-dependent in vivo,w e
expected to observe a Mef2c down-regulation in Tbx1
gain-of-function mutants. Whole-mount ISH was performed
on COET;Mesp1
Cre/+ embryos at E9.5; the COET (for Condi-
tional Over-Expression of Tbx1) transgene expresses Tbx1
mRNA in response to Cre recombination (10). Mesp1
Cre
drives Tbx1 expression in mesodermal domains of the
pharynx, head mesenchyme and splanchnic mesoderm
2486 Human Molecular Genetics, 2012, Vol. 21, No. 11(Fig. 3A–D). Whole-mount ISH showed a strong reduction in
Mef2c somite expression in COET;Mesp1
Cre/+ embryos
(arrowheads in Fig. 3E and H) and a mild Mef2c down-
regulation in the SHF (ovals in Fig. 3G and L) or splanchnic
mesoderm (arrows in Fig. 3E, H, F and I). This different
effect upon Mef2c expression in different tissues may be due
to biological reasons (different mechanisms of regulation in dif-
ferent tissues) or to technical reasons (e.g. different levels of ex-
pression of the COET transgene or different efﬁciency of
Cre-mediated excision). We conﬁrmed that Mef2c expression
is Tbx1 dosage-dependent using qRT–PCR of mRNA from
C2C12 myoblasts transfected with different amounts of a
Tbx1-expressing vector (pCDNA-Tbx1-c-myc) (Fig. 4Aa n d
B). Western blotting (WB) analysis of nuclear protein extracts
from transfected C2C12 cells with an anti-Mef2c antibody con-
ﬁrmed negative regulation at a protein level, too (Fig. 4C).
Tbx1 interferes with Mef2c expression and muscle cell
differentiation
We tested the response of Mef2c expression to Tbx1 dosage
during skeletal muscle differentiation. C2C12 myoblasts can
be induced to differentiate, in vitro, by switching culture con-
ditions from a medium supplemented with 10% fetal bovine
serum to a medium supplemented with 2% horse serum
(32). Under these conditions, we observed an increased
expression of myogenic markers MyoD and myogenin at day
2 of differentiation (data not shown). Also Mef2c expression
was increased at day 2 and, interestingly, transfected Tbx1
inhibited this up-regulation (Fig. 4D). These data are consist-
ent with those obtained in vivo with the gain-of-function
model (Fig. 3E–L) and suggest that Tbx1 may inhibit skeletal
muscle differentiation through Mef2c down-regulation. To
further support this hypothesis, we transfected C2C12 cells
with Tbx1, let them differentiate for 5 days and test different
skeletal muscle differentiation markers by qRT–PCR.
Results showed that while Myogenin did not change in re-
sponse to Tbx1 transfection, all the genes encoding muscle
structural proteins tested (Myh1, 2, 8 and Acta1) were signiﬁ-
cantly down-regulated (Supplementary Material, Fig. S1).
However, myotube formation did not appear to be grossly
affected (data not shown).
Tbx1 inhibits Gata4- but not Isl1-induced up-regulation of
Mef2c activity
To test the effects of Tbx1 upon Mef2c transcriptional activity,
we performed luciferase assays using a MEF2 luciferase report-
er construct (desMEF2-luc) on transfected C2C12 cells (33,34).
With this reporter, luciferase activity is proportional to active
MEF2 transcription factors. Mef2b is expressed at a very low
level in these cells (data not shown); Mef2a and Mef2d are
Figure 1. Cluster analysis of differentially expressed genes across the allelic series. Lines represent the average proﬁle of each cluster and the shaded areas
represent the error (SD). Proﬁles were obtained by plotting the log ratios of all dosage points with respect to the control (wt) point for all genes, and then,
the average proﬁle, for each cluster, was determined. Tbx1 proﬁle in Cluster 2 is highlighted by black circles. The transcript content of each cluster is listed
on Supplementary Material, Table S4.
Human Molecular Genetics, 2012, Vol. 21, No. 11 2487Figure 2. Mef2c is up-regulated in Tbx1 loss-of-function mutants. (A) qRT–PCR analysis showed Mef2c up-regulation in Tbx1-null mutant embryos compared
with wt littermates at E9.5. Values are means+standard error (SE), n ¼ 3, ∗P , 0.05. (B–I) Mef2c is up-regulated (arrows) and ectopically expressed (arrow-
heads) in the SHF of Tbx1
2/2 mutants (G and I) compared with wt littermates at E9.5 (C and E), as shown by section ISH. (C and E) and (G and I) are high-
magniﬁcation views of the same wt (B and D) and mutant sections (F and H) respectively.
Figure 3. Mef2c is down-regulated in Tbx1 gain-of-function mutants. (A–L) Left- and right-side views of whole wt (A, B and E–G) and COET; Mesp1
Cre/+
mutants (C, D, H, I and L) at E9.5. Tbx1 is over-expressed in the mesodermal domains of the pharynx, head mesenchyme and splanchnic mesoderm of COET;
Mesp1
Cre/+ mutants (C and D) compared with wt littermates (A and B). Mef2c is mildly down-regulated in the SHF (ovals in G and L) and splanchnic mesoderm
(arrows in E, F, H and I), and more extensively in the somites (arrowheads in E and H) of COET; Mesp1
Cre/+ mutants (H, I and L) compared with wt littermates
(E, F and G).
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Tbx1 over-expression (Supplementary Material, Fig. S2). Luci-
ferase activity increased in response to Gata4 or Isl1 transfec-
tion of C2C12 cells, conﬁrming the ability of Gata4 and Isl1
to activate Mef2c transcription (35) also in this system
(Fig. 5A and B). Transfection of a Tbx1 expression vector
alone did not affect luciferase activity (Fig. 5A). However,
co-transfection of Tbx1 and Gata4 showed that Tbx1 inhibited
the ability of Gata4 to transactivate the reporter (Fig. 5C). In
contrast, Tbx1 did not inhibit the Isl1-induced activation of
the reporter (Fig. 5D), suggesting that Tbx1 may regulate
Mef2c expression through a Gata4-dependent mechanism.
It has been shown that Gata4 is up-regulated in Tbx1
2/2
mutants (13). We analyzed Gata4 expression at E8.5 and
E9.5 by whole-mount ISH on control and COET;Mesp1
Cre/+
mutant embryos, and we found a marked Gata4 down-
regulation in COET;Mesp1
Cre/+ mutant hearts (Fig. 6C and
D) compared with control embryos (Fig. 6A and B), thus con-
ﬁrming that Tbx1 can negatively affect Gata4 expression.
Since Mef2c is regulated by Gata4 (13), one can argue that
reduced Mef2c expression observed in our experiments is
merely the result of Gata4 down-regulation by Tbx1.
However, this is unlikely since we performed our luciferase
assays on cells transfected with a Gata4 expression vector,
which is not regulated by Tbx1. Indeed, co-transfection of
Tbx1 did not affect the amount of protein produced by the
Gata4 expression vector (Supplementary Material, Fig. S3).
Gata4 is required for Tbx1-induced regulation of Mef2c in
C2C12 cells
The previous experiments support the existence of a
Tbx1-|Gata4 Mef2c pathway, but this is not sufﬁcient to
explain all our data. To test whether Tbx1 regulates Mef2c
transcription through a mechanism involving Gata4, we eval-
uated the response of Mef2c to Tbx1 in the absence of Gata4.
C2C12 myoblasts express endogenous Gata4, so, using
Gata4-speciﬁc siRNAs, we knocked down the mRNA and
protein levels to  20% of the wt level (Fig. 7A and B).
Gata4 knockdown was associated with down-regulation of
Mef2c to  80% of the wt level (Fig. 7C). Transfection of
Tbx1 (Fig. 7D) did not result in further signiﬁcant reduction
in Mef2c expression (Fig. 7C), suggesting that Gata4 is
required for Tbx1-induced down-regulation of Mef2c.
Tbx1 occupies conserved regions of the Mef2c gene
We performed a bioinformatic analysis to look for potential
TBEs evolutionary conserved between the human and the
mouse, in the Mef2c locus (see Materials and Methods). One
Figure 4. Tbx1 negatively regulates Mef2c expression in C2C12 myoblasts. (A–C) Mef2c mRNA and Mef2c protein levels are affected by Tbx1 dosage in
transfected C2C12 myoblasts as conﬁrmed by qRT–PCR (A and B) and WB analysis (C). (D) qRT–PCR analysis showed Tbx1-dependent inhibition of
Mef2c up-regulation during in vitro C2C12 myoblast differentiation. Values are means+SE, n ¼ 3, ∗P , 0.05.
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etal muscle-speciﬁc control region (36) upstream of Mef2c
(Supplementary Material, Fig. S4A).
We also found a putative TBE in a conserved SHF-speciﬁc
enhancer (Supplementary Material, Fig. S4B), previously
described by Dodou et al. (35).
Chromatin immunoprecipitation (ChIP) experiments on
C2C12 cells revealed that endogenous Tbx1 occupies both
these sites (Fig. 8), suggesting that it may have a direct role
in Mef2c transcriptional regulation.
Next, we carried out luciferase assays using a reporter con-
struct carrying the SHF enhancer (SHF-Enh-Luc; Fig. 9A) to
test its response to Tbx1 in C2C12 cells. The enhancer
responded to transfected Isl1 and Gata4 but not to transfected
Tbx1 alone (Fig. 9B). In addition, as shown in the experiment
with the desMEF2 reporter, Tbx1 did not inhibit Isl1-induced
activation, but did interfere with Gata4-induced activation
(Fig. 9C and D). The mutation of the TBE site resulted in a
signiﬁcant reduction in the response to Gata4 and in a
milder, but still signiﬁcant response to Tbx1 co-transfection
(Fig. 9D). Thus, in this assay, the TBE is not completely
required for Tbx1 to carry out its negative effect upon Gata4
activation, although this effect appears to be milder.
Figure 5. Tbx1 inhibits Gata4-dependent activation of the MEF2 reporter construct in luciferase assays. (A and B) Gata4 and Isl1 are able to activate the MEF2
reporterconstructintransfectedC2C12cells(AandB)whileTbx1isnotabletorepressit(A).(CandD)Tbx1isabletocontrastsGata4-(C)butnotIsl1-dependent
activation of the MEF2 reporter construct (D). Luciferase activity was normalized to b-galactosidase activity. Values are means+SE, n ¼ 3, ∗P , 0.05.
Figure 6. Tbx1 affects Gata4 expression in vivo.( A–D) Whole-mount ISH
showing Gata4 down-regulation in the heart of COET; Mesp1
Cre/+ mutant
embryos (C and D) compared with wt (A and B) littermates at E8.5 and
E9.5. Arrows indicate the inﬂow region of the heart.
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Dosage of Tbx1 correlates well (though often not linearly) to
phenotypic severity in vivo (9). With this work, we initiated
an effort to correlate phenotypic changes with genome-wide
transcriptional analysis, in order to identify candidate effectors
that may be closely correlated with different phenotypic fea-
tures. The experimental approach used here has some limita-
tions, e.g. the whole embryo RNA analysis might smooth
out or even hide tissue-speciﬁc changes of expression. In add-
ition, stage-speciﬁc differences cannot be detected by our
single-stage analysis. Nevertheless, our study was sufﬁcient
to identify a relatively subtle expression modulation of the
Mef2c gene, which encodes a transcription factor critical in
cardiac differentiation. In vivo and in vitro gain- and
loss-of-function studies conﬁrmed the negative correlation
between Tbx1 and Mef2c expression. This ﬁnding is consistent
with the previously determined ability of Tbx1 to inhibit car-
diomyocyte differentiation in vivo and in vitro (14). Our study
also indicates that Tbx1 over-expression has inhibitory effects
upon Mef2c expression during skeletal muscle differentiation.
We asked how Tbx1 down-regulates Mef2c expression. Our
data suggest three, non-mutually exclusive, mechanisms
(Fig. 10). One is direct interaction with the Mef2c gene
Figure 7. Gata4 is required for Mef2c repression by Tbx1 in C2C12 myoblasts. (A and B) siRNA-mediated knockdown of Gata4 results in a reduction in mRNA
and protein levels to  20% of the wt level, as conﬁrmed by qRT–PCR (A) and WB analysis (B). (C and D) qRT–PCR showed that Gata4 knockdown and Tbx1
over-expression result, independently, in Mef2c down-regulation (C and D and Fig. 4A and B). In the absence of Gata4, over-expression of Tbx1 does not result
in further reduction in Mef2c expression (C). Values are means+SE, n ¼ 3, ∗P , 0.05.
Figure 8. Endogenous Tbx1 binds conserved regulatory regions in the Mef2c
locus. Small panel top-right: WB analysis of C2C12 nuclear extracts using an
anti-Tbx1 antibody demonstrating endogenous expression of the protein.
Graph: chromatin immunoprecipitation analysis of the Mef2c skeletal
muscle and SHF TBEs performed in C2C12 myoblasts using an antibody
against Tbx1 together with rabbit IgG as the background control. qRT–PCR
analysis of an immunoprecipitated material was performed and percent of
input for each sample is reported in the graph. Values are means+SD, n ¼ 3.
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Tbx1. The consequences of this interaction remain to be inves-
tigated, but they may be chromatin changes leading to tran-
scriptional down-regulation. Our luciferase assay with a
mutated TBE in the SHF resulted in very limited reduction
in the capacity of Tbx1 to inhibit enhancer activity.
However, because enhancer constructs are not properly chro-
matinized and are out of the normal context of the endogenous
gene, it is difﬁcult to draw conclusions from these data.
The second mechanism is mediated by a repressive effect of
Tbx1 upon Gata4 gene expression (Fig. 10), as seen in vivo
(13) (data presented here). This mechanism is supported by
tissue culture data, showing that silencing Gata4 suppresses
the ability of Tbx1 to down-regulate Mef2c in C2C12 cells.
This effect would have negative consequences upon the ex-
pression of Mef2c because this gene is a target of Gata4.
However, our desMEF2 reporter data indicate that Tbx1 is
able to inhibit reporter activation in the presence of transfected
Gata4, and in this scenario, the transcriptional regulation of
the Gata4 gene is irrelevant. It is more likely that Tbx1 inter-
feres negatively upon the ability of the Gata4 protein to
regulate Mef2c (Fig. 10). The third mechanism is also compat-
ible with the results obtained by Gata4 knockdown (Fig. 7).
Tbx20 synergizes with Gata4 (and Isl1) to activate both the
Mef2c and Nkx2.5 SHF enhancers (37); Tbx1 may compete
with another T-box protein and inhibit this synergy. Interest-
ingly, in our luciferase assay with the SHF enhancer, the mu-
tation of the TBE site signiﬁcantly reduced the ability of Gata4
to activate the enhancer. This might be because of an endogen-
ous T-box protein that synergizes with Gata4 in C2C12 cells.
However, this is not Tbx20, as the gene encoding it is not
expressed in these cells (our unpublished data). In addition,
Gata4 and Tbx5 co-immunoprecipitate and cooperatively
transactivate a luciferase atrial natriuretic factor reporter
(38). However, Tbx1 does not co-immunoprecipitate with
Gata4 in C2C12 cells (data not shown). Of note,
co-transfection experiments showed the ability of Nkx2-5
and GATA4 to transactivate the minimal Cx40 promoter,
while Tbx5 repressed Nkx2-5/GATA4-mediated activation
(39), demonstrating that T-box transcription factors could ac-
tivate or repress transcription, depending on the speciﬁc
context.
Figure 9. Response of the Mef2c SHF enhancer to Tbx1 expression in luciferase assays. (A) Scheme of the Mef2c SHF enhancer–luciferase construct. The
sequence of the mutant TBE is indicated. (B) The enhancer responds well to graded amounts of transfected Isl1 and Gata4 but not to Tbx1. (C) Tbx1 does
not signiﬁcantly affect Isl1-induced activation of the enhancer. (D) Luciferase assay using a wt (black bars) or mutated (white bars) SHF enhancer. In both
cases, Tbx1 can reduce Gata4-induced activation of the enhancer. However, the mutant SHF responds less well to Gata4, and Tbx1 inhibition is less
obvious. Luciferase activity was normalized to b-galactosidase activity. Values are means+SE, n ¼ 3, ∗P , 0.05.
2492 Human Molecular Genetics, 2012, Vol. 21, No. 11In summary, our results illustrate the power of multiallelic
gene expression analysis as it identiﬁed a relatively subtle
regulation of a gene encoding a developmentally critical tran-
scription factor. The mechanisms by which Tbx1 regulates
Mef2c expression appear to be complex and include direct
interaction with the gene, regulation of Gata4 expression,
which in turn regulates Mef2c, and possibly interference
with the Gata4 protein ability to regulate Mef2c.
The identiﬁcation of the negative regulation of Mef2c by
Tbx1 provides an additional clue as to how Tbx1 carries out
its negative modulation of cardiomyocyte differentiation and
provides a new link in the genetic network operating in
cardiac progenitor cells.
MATERIALS AND METHODS
Mouse lines, breeding and genotyping
All the mouse mutant alleles used in this study have been pre-
viously reported: Tbx1
2 (7), Tbx1
Neo (11), Tbx1
Neo2 (12),
COET (10) and Mesp1
Cre (40). The COET transgene (10)
upon Cre-mediated recombination in average expresses a
Tbx1 cDNA approximately twice as much as the level of
one endogenous Tbx1 allele (10).
Various homozygous and compound heterozygous mutants
were generated by heterozygous mutant mating. Embryos
were collected at E8.5 and E9.5, considering the day of obser-
vation of a vaginal plug to be E0.5. Mice were genotyped by
PCR as described in the original reports.
Cell lines, plasmids and transfections
Mouse C2C12 myoblasts (ATCC) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Invitrogen) supplemented
with 10% fetal bovine serum (Hyclone) at 378C with 5% CO2.
To allow cells to differentiate, medium was changed to
DMEM medium supplemented with 2% horse serum
(Hyclone).
We have previously described the pCDNA-Tbx1-c-myc ex-
pression vector (11). The desMEF2-luc reporter construct (33)
was kindly provided by Dr Eric N. Olson; the
pCDNA3.1-Gata4-c-myc-His and pCDNA3.1-Ils1 were
kindly provided by Dr Robert J. Schwartz.
The SHF-Enh-Luc reporter construct was generated by
cloning the SHF minimal enhancer of the mouse Mef2c gene
described by Dodou et al.( 35) into the pGL3- Promoter
Vector (Promega). The mutated SHF-Enh-Luc reporter con-
struct was generated by substitution of three nucleotides in
the conserved TBE of the original SHF-Enh-Luc reporter con-
struct, using the QuikChange II Site- Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions.
C2C12 cells were transiently transfected using the PolyFect
Transfection Reagent (QIAGEN) according to the manufac-
turer’s instructions; cells were collected 24 h after transfection
for RNA or protein extraction.
For differentiation experiments, 24 h after transfection,
medium was changed to differentiation medium and cells
were collected at different days for RNA extraction.
Microarray-based gene expression analysis
Total RNA from E9.5 embryos with nine different genotypes
(Tbx1
+/+, Tbx1
Neo2/+, Tbx1
Neo/+, Tbx1
+/2, Tbx1
Neo2/Neo2,
Tbx1
Neo2/Neo, Tbx1
Neo2/2, Tbx1
Neo/Neo and Tbx1
2/2) was iso-
lated using TRIzol (Invitrogen) and cleaned using the
RNeasy cleanup Kit (QIAGEN) according to the manufac-
turer’s instructions. Procedures for cRNA preparation and
GeneChip processing were performed at Boston University
Microarray Resource Facility exactly as described in the Affy-
metrix GeneChip Expression Analysis Technical Manual
(Affymetrix, Santa Clara, CA, USA, current version available
at www.affymetrix.com). Brieﬂy, total RNA integrity was
veriﬁed using RNA 6000 Nano Assay RNA chips run in
Agilent 2100 Bioanalyzer (Agilent Technologies). Total
RNA was reverse transcribed using One Cycle cDNA Synthe-
sis kit (Affymetrix) and the obtained double-stranded cDNA
was puriﬁed with GeneChip Sample Cleanup Module (Affy-
metrix). cDNA was used as a template for in vitro transcrip-
tion using GeneChip in vitro transcription (IVT) Labeling
Kit (Affymetrix). The obtained biotin-labeled cRNA was puri-
ﬁed using GeneChip Sample Cleanup Module (Affymetrix),
fragmented and hybridized (10 mg) to the GeneChip Mouse
430 2.0 microarrays (Affymetrix) for 16 h in GeneChip Hy-
bridization oven 640 at 458C. For each genotype, we used
two biological replicates, each hybridized to one array, with
a total of 18 arrays. IVT and cRNA fragmentation quality con-
trols were carried out by running an mRNA Nano assay in the
Agilent 2100 Bioanalyzer. The hybridized samples were
washed and stained using Affymetrix ﬂuidics station 450
with streptavidin-R-phycoerythrin (SAPE) and the signal
was ampliﬁed using a biotinylated goat anti-streptavidin anti-
body followed by another SAPE staining (Hybridization,
Washing and Staining Kit, Affymetrix). Microarrays were im-
mediately scanned using Affymetrix GeneArray Scanner 3000
7G Plus (Affymetrix). The data were analyzed with the
Figure 10. Schematic model of Mef2c regulation by Tbx1. Our data suggest
three, non-mutually exclusive, mechanisms: (i) direct transcriptional regula-
tion of Mef2c by Tbx1; (ii) negative regulation of Gata4 expression and (iii)
interference with Gata4-dependent activation of Mef2c (double-dashed line).
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Average method for normalizing and summarizing probe
level intensity measurements.
Statistical analysis of microarray data
We developed a strategy for statistical comparison of chip data
aimed at identifying genes that responded to variations of Tbx1
dosage. To discover which genes responded signiﬁcantly, we
computed the log ratio of all dosage points with respect to
the control (wt) point for all genes. After this, we used a
two-step ﬁltering: in the ﬁrst step, we made the assumption
that if a gene is not responding to the dosage variation, then
the area under the gene proﬁle curve should be close to
zero. We approximated this area by summing the square of
the relative expression levels of all genes. Under the null hy-
pothesis that a gene is not responding in the dosage series, this
area should be close to zero, otherwise it should be higher. We
approximated the area distribution with an exponential prob-
ability density function with the mean equal to the average
of the area of all transcripts in the microarray. By using a
P-value of 0.05, we selected a list of 2230 transcripts, includ-
ing Tbx1 (Supplementary Material, Table S1).
In the second step, we performed a more stringent test based
on a Bayesian analysis of signals (41). This fully Bayesian ap-
proach allowed us to automatically identify and rank 497 dif-
ferentially signiﬁcant genes, whose expression is sensitive to
Tbx1 dosage (Supplementary Material, Table S2).
GO and cluster analyses
GO analysis (http://david.abcc.ncifcrf.gov/) was performed to
identify speciﬁc biological pathways enriched in the list of 498
differentially expressed genes. The most signiﬁcant terms
included regulation of metabolic processes and regulation of
gene expression (false discovery rate , 0.05).
Hierarchical clustering was performed on the list of 498 dif-
ferentially expressed genes using the MATLAB software (http
://www.mathworks.it/help/toolbox/stats/bq_679x-3.htm
l#bq_6_ia). Four main clusters were identiﬁed and, for each
cluster, we calculated the average proﬁle and the associated
standard deviation (SD).
TBE search
Upstream and intronic genomic sequences for human and
mouse Mef2c were obtained from both the Ensembl and
UCSC Genome Browser web sites and were aligned using
the multisequence local alignment tool MULAN (http://mula
n.dcode.org/). No speciﬁc Tbx1-binding consensus sequence
has been identiﬁed so far; however, Tbx1 can activate, in
vitro, the Fgf10 promoter, through a conserved Tbx5-binding
site (11). Multi-TF (http://multitf.dcode.org) transcription
factor-binding site analysis was performed to ﬁnd evolutionary
conserved Tbx5-binding elements, in the aligned sequences.
With this approach, we uncovered several TBEs in the
Mef2c locus.
Quantitative real-time PCR
Total RNA was extracted from whole E9.5 wt and mutant
embryos using TRIzol (Invitrogen) and from C2C12 using
the RNeasy Mini Kit (QIAGEN). One microgram of total
RNA was reverse transcribed using SuperScript III (Invitro-
gen) according to the manufacturer’s instructions, in a total
volume of 20 ml; the resulting cDNA was diluted 1:10.
qRT–PCR was performed using SYBR Green for the detec-
tion of ﬂuorescence during ampliﬁcation. Each ampliﬁcation
reaction contained 25 ml of Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen), 0.2 mg each of forward and
reverse primers and 1 ml of diluted cDNA. All primers were
designed with annealing temperatures of 58–628C. PCR con-
ditions were: 508C for 2 min, 958C for 10 min, 40 cycles of
958C for 15 s, 608C for 1 min and followed by a dissociation
stage of 958C for 15 s and 608C for 15 s. All the genes were
ampliﬁed on a 7900 HT Fast Real-Time PCR System
(Applied Biosystems). PCR ampliﬁcations were performed
in triplicate and at least three separate analyses were carried
out for each gene. Melting curve analysis was performed
after each run to check for the presence of non-speciﬁc PCR
products and primer dimers. The qRT–PCR results, recorded
as threshold cycle numbers (Ct) were normalized using
GAPDH as an internal control and analyzed using the com-
parative Ct method (2−DDCt method) (42,43).
In situ hybridization
Digoxigenin-labeled RNA probes were prepared by standard
methods (Roche). Mef2c and Gata4 probes were kindly pro-
vided by Dr Brian L. Black. Embryos were dissected in
di-ethylpolycarbonate (Sigma Aldrich)-treated phosphate-
buffered saline (PBS) and ﬁxed overnight in 4% paraformalde-
hyde–PBS (Sigma Aldrich) at 48C.
For ISH on cryosections, embryos were cryoprotected with
increasing concentrations of sucrose (Sigma Aldrich), treated
with a mixture of 1 part 30% sucrose and 1 part OCT for at
least 2 h at 48C, embedded in OCT and cut to generate 10–
12 mm sections. After post-ﬁxation in 4% paraformalde-
hyde–PBS, sections were incubated in triethanolamine
buffer (0.2% acetic acid and 1% triethanolamine, Sigma
Aldrich) containing acetic anhydride and washed twice in
PBS for 5 min. The sections were then prehybridized for 1 h
at 708C in the hybridization mixture (50% formamide from
Sigma Aldrich, 5× saline-sodium citrate (SSC), salmon
sperm DNA 40 mg/ml and 25 mg/ml yeast tRNA from Invitro-
gen). The probes were denatured for 5 min at 808C and added
to the hybridization mix (400 ng/ml). The hybridization reac-
tion was carried out over night at 708C; prehybridization and
hybridization were performed in a box saturated with a 5×
SSC–50% formamide solution to avoid evaporation. After in-
cubation, the sections were washed twice with MABT (50 mM
maleic acid, pH 7.5, 250 mM NaCl and 0.1% Tween-20, Sigma
Aldrich), treated with MABT containing 10% sheep serum for
1 h at room temperature and then incubated with alkaline
phosphatase-coupled anti-digoxigenin antibody (Roche)
diluted 1:2000 in MABT containing 10% sheep serum, over-
night at 48C. The day after, sections were washed with
MABT and equilibrated for 5 min in Buffer 3 (Tris–HCl
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velopment was performed at room temperature (time depend-
ing on the amount of transcripts to be detected) in Buffer 3
containing nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolyl phosphate (Roche). Staining was stopped by a wash
in PBS containing 0.1% Tween-20; sections were rehydrated
for 5 min in deionized water and then dehydrated through suc-
cessive baths of EtOH (70, 95 and 100%) and xylol, and
mounted in Eukitt resin (O. Kindler GmbH & Co.).
Whole-mount ISH was performed according to the previ-
ously published methods (44). At least three somite staged
wt and mutant embryos were analyzed with each probe.
Western blotting
Nuclear proteins were extracted as described previously (18).
The following primary antibodies were used: rabbit anti-Tbx1
(Abcam, 1:1000), goat anti-Mef2c (Santa Cruz Biotechnology,
1:1000), rabbit anti-Gata4 (Santa Cruz Biotechnology,
1:1000), monoclonal anti-c-myc (Sigma-Aldrich 1:1000) and
monoclonal anti-b-Actin (Sigma-Aldrich 1:10000). The fol-
lowing secondary antibodies were used: horseradish
peroxidase-conjugated (HRP) anti-rabbit and anti-mouse (GE
Healthcare, 1:10000) and HRP-conjugated anti-goat (Santa
Cruz Biotechnology, 1:5000). The HRP-derived signal was
detected using the Amersham ECL and ECL Plus Western
Blotting Detection Reagents (GE Healthcare).
Luciferase assay
For luciferase assays, mouse C2C12 myoblasts were plated in
24-wells and transfected with PolyFect Transfection Reagent
(QIAGEN) according to the manufacturer’s instructions. The
desMEF2-luc reporter construct and, for single experiments,
the pCDNA-Tbx1-c-myc, pCDNA3.1-Gata4-c-myc-His and
pCDNA3.1-Ils1 plasmids were always co-transfected with a
pCMV-b-Gal expression vector (Clontech); at 24 h after trans-
fection, cell extracts were prepared and activities of
b-galactosidase and Fireﬂy luciferase were measured using
the Luciferase Assay System (Promega) and the Beta-Glo
Assay System (Promega), respectively, on a GLOMAX 96
microplate luminometer (Promega). Relative luciferase activ-
ity (Fireﬂy luciferase for reporter and b-galactosidase for nor-
malization of transfection efﬁciency) was measured following
manufacturer’s instructions (Promega). The data represent the
means and SDs of at least three independent transfections.
RNA interference
Gata4 interference in C2C12 myoblasts was achieved by using
a set of four different siRNAs speciﬁcally directed against the
mouse Gata4 locus (ON-TARGET plus SMART Pool,
Thermo Scientiﬁc). As negative control, we used a pool of
siRNAs that virtually targeted no mouse genes (ON-TARGET
plus Negative Control, Thermo Scientiﬁc). Cells were plated
in six wells and transfected with 50 nM/well of siRNAs
using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. The Gata4 mRNA level was mea-
sured by qRT–PCR and the Gata4 protein level by WB as
described above.
ChIP assay
ChIP assay was performed as described previously (45). Son-
ication was performed for 10 cycles of 15 s on and 60 s off
using a Soniprep 150 (Measuring and Scientiﬁc Equipment).
Immunoprecipitation was performed overnight at 48C with
an antibody against Tbx1 (Abcam, 4/100 mg of chromatin);
normal rabbit immunoglobulin G (IgG) was used as the back-
ground control.
Results were quantiﬁed by qRT–PCR using the primers
listed in Supplementary Material, Table S3, and the enrich-
ment of DNA was calculated in terms of percent of input, as
described previously (46). PCR ampliﬁcations were performed
in triplicate from three independent experiments.
Statistical analysis
All data were expressed as means+standard error or SD from
three independent experiments. Differences between groups
were examined for statistical analysis using a two-tailed Stu-
dent’s t-test. Values of P , 0.05 were considered signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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